Insider Selling: CeriBell, Inc. (NASDAQ:CBLL) Director Sells $342,800.00 in Stock

CeriBell, Inc. (NASDAQ:CBLL) Director Rebecca B. Robertson sold 20,000 shares of the business’s stock in a transaction dated Monday, June 16th. The stock was sold at an average price of $17.14, for a total transaction of $342,800.00. Following the transaction, the director now owns 28,675 shares in the company, valued at approximately $491,489.50. This trade represents a 41.09% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

CeriBell Price Performance

Shares of CBLL opened at $17.80 on Friday. The company has a debt-to-equity ratio of 0.11, a quick ratio of 16.81 and a current ratio of 17.36. The firm’s 50-day moving average is $16.61 and its two-hundred day moving average is $20.83. CeriBell, Inc. has a twelve month low of $10.01 and a twelve month high of $32.75.

CeriBell (NASDAQ:CBLL) last released its quarterly earnings results on Thursday, May 8th. The company reported ($0.36) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.43) by $0.07. The firm had revenue of $20.49 million during the quarter, compared to analyst estimates of $19.30 million. As a group, sell-side analysts expect that CeriBell, Inc. will post -2.46 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research firms have issued reports on CBLL. LADENBURG THALM/SH SH began coverage on CeriBell in a research report on Friday, April 4th. They set a “buy” rating and a $32.00 target price on the stock. Canaccord Genuity Group reaffirmed a “buy” rating and set a $33.00 price objective on shares of CeriBell in a report on Wednesday, February 26th. Seven equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company has an average rating of “Buy” and a consensus price target of $32.50.

Institutional Trading of CeriBell

Several large investors have recently bought and sold shares of CBLL. FMR LLC acquired a new stake in CeriBell in the fourth quarter valued at $128,120,000. TPG GP A LLC acquired a new stake in CeriBell in the 4th quarter valued at about $102,677,000. Red Tree Management LLC acquired a new stake in CeriBell in the 4th quarter valued at about $57,083,000. Yu Fan acquired a new stake in CeriBell in the 4th quarter valued at about $31,631,000. Finally, ABG WTT Global Life Science Capital Partners GP Ltd acquired a new stake in shares of CeriBell in the fourth quarter valued at approximately $28,160,000.

CeriBell Company Profile

We are a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. We have developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting.